First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients

Phase 2 Recruiting 58 enrolled Fudan University

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a multicenter, open-label, exploratory study to evaluate the efficacy and safety of QL1706 plus nab-paclitaxel and gemcitabine with or without bevacizumab as first-line treatment in patients with unresectable locally advanced or metastatic pancreatic cancer

Timeline

Start: 2024-06-20
Primary completion: 2025-10-31
Completion: 2026-10-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	7.5 mg/kg	Intravenous
Subject	Gemcitabine	Small molecule	1000 mg/m2	Intravenous
Subject	Paclitaxel	Small molecule	125 mg/m2	Intravenous
Subject	QL1706	Monoclonal antibody	5 mg/kg	Intravenous

First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients

Summary

Timeline

Drugs

Indications